We conditionally recommend treatment with azathioprine/6-mercaptopurine, calcineurin inhibitors, NSAIDs and the non-TNF inhibitor biologic agents (anakinra, rituximab, belimumab, abatacept, tocilizumab, secukinumab, and ustekinumab) as compatible with breastfeeding We strongly recommend against use of CYC, leflunomide, MMF, and thalidomide while breastfeeding. We conditionally recommend against use of MTX while breastfeeding. Despite minimal passage of MTX into breast milk, especially with